IA
CRNX

IFP Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

IFP Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54K Hold
1,443
– – ﹤0.01% 2352
2026
Q1 		$52.4K Sell
1,443
-3
-0.2% -$134 ﹤0.01% 2213
2025
Q4 		$67.3K Hold
1,446
– – ﹤0.01% 2021
2025
Q3 		$60.2K Buy
1,446
+91
+7% +$2.91K ﹤0.01% 1979
2025
Q2 		$44.4K Sell
1,355
-86
-6% -$2.66K ﹤0.01% 2106
2025
Q1 		$48.7K Sell
1,441
-19
-1% -$710 ﹤0.01% 1906
2024
Q4 		$75.2K Buy
1,460
+44
+3% +$2.46K ﹤0.01% 1616
2024
Q3 		$72.4K Sell
1,416
-59
-4% -$3.04K ﹤0.01% 1556
2024
Q2 		$66.1K Sell
1,475
-15
-1% -$693 ﹤0.01% 1548
2024
Q1 		$69.8K Buy
+1,490
New +$58.3K ﹤0.01% 1453

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's CRNX Position: Q2 2026 in Review

IFP Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 1,443 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #2352.

IFP Advisors first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $75.2K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • IFP Advisors held 1,443 shares of Crinetics Pharmaceuticals worth $54K as of Q2 2026.
  • IFP Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2352 holding.
  • IFP Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • IFP Advisors's Crinetics Pharmaceuticals position peaked at $75.2K in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.